Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Keytruda Pembrolizumab
Lynparza Olaparib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Tafinlar and Mekinist Dabrafenib and Trametinib NSCLC BRAF V600 Complete
Kineret anakinra Still's disease Suspended
Ledaga chlormethine hydrochloride T-cell lymphoma Active
Tysabri natalizumab Multiple Sclerosis, relapsing-remitting Suspended